Back to results
US 2026/0177562 A1Published application
Assays to detect neurodegeneration
AssigneeJanssen Pharmaceutica NV
InventorsHartmuth Christian Kolb, Gallen Triana-Baltzer, John Randall Slemmon
Life of this patent
Estimating the term…
Abstract
Methods of measuring the amount of singly- or multiply-phosphorylated p217+ tau protein in a sample are provided. Methods of detecting or diagnosing tauopathies, methods of determining the effectiveness of a treatment of a tauopathy, and methods of determining whether a subject is suitable for anti-p217+ tau antibody therapy are also provided. Also described are antibodies for use in the methods and kits comprising the antibodies.
Claims21
1-21. (canceled)
A method of measuring p217+ tau peptides in a sample, comprising:
- (a) contacting the sample with a capture antibody comprising an immunoglobulin heavy chain HCDR1, HCDR2 and HCDR3 comprising the polypeptide sequences of SEQ ID NOs:
- 32, 33 and 34, respectively and an immunoglobulin light chain LCDR1, LCDR2 and LCDR3 comprising the polypeptide sequences of SEQ ID NOs:
- 35, 36 and 37, respectively to capture the p217+ tau peptides in the sample, and
- (b) contacting the captured p217+ tau peptides from (a) with at least one of a detection antibody selected from
- (i) an antibody comprising an immunoglobulin heavy chain HCDR1, HCDR2 and HCDR3 comprising the polypeptide sequences of SEQ ID NOs:
- 12, 13 and 14, respectively and an immunoglobulin light chain LCDR1, LCDR2 and LCDR3 comprising the polypeptide sequences of SEQ ID NOs:
- 15, 16 and 17, respectively and
- (ii) antibody comprising an immunoglobulin heavy chain HCDR1, HCDR2 and HCDR3 comprising the polypeptide sequences of SEQ ID NOs:
- 2, 3 and 4, respectively and an immunoglobulin light chain LCDR1, LCDR2 and LCDR3 comprising the polypeptide sequences of SEQ ID NOs:
- 5, 6 and 7, respectively
- to thereby measure the p217+ tau peptides.
8 more elements
Dependencies are inferred from the claim text.